Sign In
Buy COR
$306.28
-2.09 (-0.678%)
At Close: Aug 04, 2026
Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript
06:02pm, Tuesday, 09'th Sep 2025
Cencora, Inc. (NYSE:COR ) Baird Global Healthcare Conference 2025 September 9, 2025 3:45 PM EDT Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury James Cleary - Ex
Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
11:11am, Friday, 05'th Sep 2025
Cencora, Inc. (NYSE:COR ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:45 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Head of In
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
09:11am, Friday, 05'th Sep 2025
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Here's Why Cencora (COR) is a Strong Value Stock
10:41am, Monday, 01'st Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
COR vs. MEDP: Which Stock Is the Better Value Option?
12:41pm, Thursday, 28'th Aug 2025
Investors with an interest in Medical Services stocks have likely encountered both Cencora (COR) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
10:21am, Thursday, 28'th Aug 2025
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, HWM, COR and CAKE are some such stocks.
Cencora Appoints Mark Durcan as Chairman of Its Board of Directors
04:15pm, Wednesday, 27'th Aug 2025
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors,
Cencora (COR) is an Incredible Growth Stock: 3 Reasons Why
01:45pm, Wednesday, 27'th Aug 2025
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year?
10:41am, Wednesday, 20'th Aug 2025
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Why Cencora (COR) is a Top Value Stock for the Long-Term
10:41am, Friday, 15'th Aug 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap
02:31pm, Tuesday, 12'th Aug 2025
Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x for
3 Reasons Growth Investors Will Love Cencora (COR)
01:46pm, Monday, 11'th Aug 2025
Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy
05:08pm, Friday, 08'th Aug 2025
I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and
Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript
12:25pm, Wednesday, 06'th Aug 2025
Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
11:31am, Wednesday, 06'th Aug 2025
Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.
